Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain.

• The 28 patients were dosed for six months and followed for three more. The goal of the study was safety and tolerability.

• ANX005 demonstrated full and durable C1q target inhibition as measured by two biomarkers.

• Results showed stabilization of disease progression in the overall population for the entire nine months of the study.

• Related: Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer.

• Three dropouts were potentially linked to the treatment. The adverse events experienced by the three patients included a case of systemic lupus and idiopathic pneumonitis, a type of noninfectious pneumonia. But no serious cases of infection or death were reported.

• According to the final data release, the case of lupus resolved after treatment stopped, while the idiopathic pneumonitis event "improved" once dosing ceased.

• The third patient experienced hemolytic anemia, which was asymptomatic and also resolved with the end of treatment.

• Annexon plans to talk with regulators in the U.S. and the EU to discuss the design of a well-controlled confirmatory trial.

• ANX005 is also tested for amyotrophic lateral sclerosis, Guillain Barré syndrome, and warm autoimmune hemolytic anemia.

• Price Action: ANNX shares are up 16.3% at $3.78 during the market session on the last check Tuesday.

See more from Benzinga

• Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

• AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.